Medial EarlySign

Medial EarlySign was pleased to be part of a team that delivered a poster presentation at the American Society of Clinical Oncology (ASCO) in June 2024. The research highlighted the development of a budget impact model based on the adoption of LungFlag™ (a validated clinical AI model) as an adjunct to existing screening guidelines for USPSTF-eligible patients. Using a hypothetical US health plan population of 1-million beneficiaries, there were 36,803 USPSTF-eligible persons for low-dose CT screening (LCS). Assuming 4,600 (12.5%) had already initiated LCS, that left 32,203 persons to be pre-screened by LungFlag, which was configured to select top 3% (990) for further assessment by LCS.  The use of Lung Flag on this population was estimated to prevent 22 additional NSCLC-related deaths, with a cost savings of $2.87 million over 5 years from a US commercial payer perspective. The poster provides additional details around total population size, screening eligibility, and more. In conjunction with researchers from Roche, Kaiser Permanente, and Genentech we are pleased to make this research available and support industry-wide efforts to demonstrate how AI models can have a truly beneficial impact on early detection of serious disease. We invite you to download the full Poster. https://lnkd.in/gQBMJkKH #earlydetection #clinicalAI

The Value of Clinical Labs in Early Detection, Precision Treatment Plans, and Effective Therapies In the highly complex and intricate landscape of healthcare, clinical laboratories often go unnoticed, yet their contribution is indispensable. These labs are the backbone of medical diagnostics, providing critical data that empowers physicians to make evidence-based decisions. Early detection can be a cornerstone component of effective treatment, and clinical labs are at the forefront of this effort. With advanced testing capabilities, they help identify serious diseases at their nascent stages, with the potential to significantly improve patient outcomes. From detecting cancer markers to identifying infectious agents, clinical labs play a pivotal role in the diagnostic process. The data generated by these labs enable physicians to tailor treatment plans with precision, ensuring that patients receive the most effective and personalized therapies. This synergy between lab scientists and physicians epitomizes the essence of personalized medicine, where treatments are not just reactive but proactive, and tailored to the individual needs of each patient. The Clinical Lab 2.0 framework supports that position that early detection strategies can be built on deployment of proactive risk stratification and finding care gaps which may ultimately lead to the earlier identification of high-risk patients for targeted intervention. As we strive towards a future where early detection and personalized medicine hopefully become the norm, the role of clinical labs will only grow in importance--driving forward the mission of saving lives and improving health. Clinical Lab 2.0 Ori Geva #PrecisionMedicine #EarlyDetection #HealthcareInnovation

We are pleased to expand our strategic partnership with Lucem Health as we work together to bring proven solutions to impact early detection for serious disease. Our collaboration demonstrates a shared vision of both companies to provide healthcare professionals with innovative tools to accelerate pathways to intervention.

For the first time, Newsweek and Statista have released their annual rankings of digital health companies. With clear and detailed methodology, the winners were selected based on financial performance, impact, and user engagement. EarlySign is pleased to be named amongst this distinguished group of health leaders making positive strides toward better health across the globe. https://lnkd.in/gsjf7JTU

Increasing colorectal cancer screening rates has been a priority in the United States for some time, as outcomes have been shown to improve significantly when asymptomatic polyps and other early-stage cancers are detected and treated early. EarlySign is pleased to support the collective efforts of Capital Digestive Care, the largest private gastroenterology (GI) practice in the Mid-Atlantic region, as they recently announced the launch of EarlySign’s LGI-Flag in the United States. Available through the Roche navify® Algorithm Suite, LGI-Flag is a groundbreaking AI-driven algorithm used to flag individuals at risk for lower GI disorders that warrant further evaluation.  https://lnkd.in/gpet5JVw

EarlySign salutes our colleague and innovation partner, David Vawdrey, PhD, chief data and informatics officer at Geisinger as he will be part of an exceptional panel of industry and clinical leaders at HIMSS entitled, “Elevating Clinical Excellence through Innovative algorithms and Clinical Decision Support.” #AIML #algorithms #healthtech #earlydetection

With #Colorectalcancer Awareness Month approaching, we appreciate the diligence of the clinicians, care givers and healthcare organizations who are striving to help promote the urgency around prevention, screening, and early detection of CRC. https://lnkd.in/gJcjHzYZ #earlydetection

With prevention and early detection at the core of our mission, EarlySign is pleased to announce another externally blinded validation to our expanding portfolio of early detection #ai powered clinical models. The most recent published model validation is focused on augmenting screening for early detection of Abdominal Aortic Aneurysm (AAA) in high-risk patients using EarlySign’s AAA-Flag. The study, entitled “Development and Validation of a Machine Learning Prediction Model to Improve Abdominal Aortic Aneurysm Screening,” was recently published in the Journal of Vascular Surgery. We are grateful to our research partners at Geisinger as we jointly sought to discover whether machine learning can significantly improve the efficiency of screening for AAA. This blinded data, retrospective study found that by selecting individuals at greatest risk for targeted screening, AAA-Flag algorithm enabled a 200% lift in the sensitivity to AAA when compared with standard screening guidelines and a potential to increase screening efficiency. It has also shown that despite a lower prevalence of AAA in females, the AAA-Flag model again significantly enhanced AAA detection when compared to standard screening guidelines. #earlydetectionsaveslives Contact Medial EarlySign for a copy of the study.

Efforts to deploy advanced, proactive approaches leveraging #EarlySign’s AI predictive models can play a significant role in identifying prediabetic patients at a higher risk of progressing to diabetes in the near term, when prevention efforts can have the most effect. Check out this recent blog post from Lucem Health as they provide perspective data around the growing burden of prediabetes and how the benefits of #earlydetection can impact screening resource allocation and potentially reduce the human and financial cost of diabetes. https://lnkd.in/gdfb5UzB

Earlier detection of Lung Cancer is a huge pain area, even with growing legitimacy and reimbursement for screening we still see soooo low rates of participation in the few programs out there, there are many high risk individuals that should get into the funnel (which by the way needs to be larger - see ACS latest recommendation https://lnkd.in/dNnCRe4r ) and are left out , we should allow smarter approaches to get the people in by more sophisticated model than just age and smoking intensity. But even just within the existing guidelines of USPSTF on ever-smokers (let alon never smokers) there is much to do to augment the screening and embrace people at higher risks to consider the screening they are eligible to do. We are so proud to have the leadership of Geisinger (and the whole team that made it happen) endorse a LungFlag based solution and take a step forward to provide better care and innovate. This is a good start. Good news in a very troubling time.